Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review

Liu, Qiuying Selina; Assad, Nour; Yi, Cecilia Arana

doi:10.1002/ccr3.3164

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the incidence rate of bosutinib-induced lung injuries is extremely low (Table 1 ). To the best of our knowledge, there are only two previous reports of lung injury during bosutinib treatment [ 5 , 6 ]. We summarized clinical characteristics including smoking history of the patients in Table 1 .…”

Section: Discussionmentioning

confidence: 99%

Bosutinib-induced lung injury: a report of two cases and literature review

et al. 2022

View full text Add to dashboard Cite

The prognosis of patients with chronic myeloid leukemia (CML) has improved dramatically since the development of tyrosine kinase inhibitors (TKIs). Three second-generation TKIs, including bosutinib, are currently approved for treatment of CML, and show a faster and deeper clinical response than imatinib. Common adverse events (AEs) of bosutinib are diarrhea and hepatic toxicity; however, lung complications are rare. Here, we report two cases of bosutinib-induced severe lung injury, along with a literature review. The events of these cases occurred at early time points and severity was extremely high, requiring high-flow oxygen and steroid treatments. Compared to previously reported cases, the prevalence and severity of the damage may vary among different ethnicities. However, bosutinib-induced lung injury can cause life-threatening complications. In conclusion, patients treated with bosutinib should be monitored carefully to mitigate serious drug-induced lung injury.

show abstract

Section: Discussionmentioning

confidence: 99%